This gene signature consists of four genes that were upregulated in the DOX/anti-PD-1 group relative to the anti-PD-1 monotherapy group, namely DIO2, PDK4, GSN, and MMP3. Not all of the proteins were previously associated with a positive prognosis in cancer. The gene discussed is GSN; the disease is cancer.